Individuals & Families
Small Businesses
Nonprofits
Employers
Employee Benefits Brokers
PEOs
Credit Unions
Membership Groups
Legal Information
Sign In
/
U.S. State Codes
/
Indiana
/
Title 12. Human Services
/
Article 15. Medicaid
/
Chapter 35. Drug Utilization Review
Chapter 35. Drug Utilization Review
12-15-35-1. "Appropriate and medically necessary" defined
12-15-35-2. "Board" defined
12-15-35-3. "Compendia" defined
12-15-35-4. "Counseling" defined
12-15-35-4.5. "Covered outpatient drug" defined
12-15-35-5. "Criteria" defined
12-15-35-6. "Drug-disease contraindication" defined
12-15-35-7. "Drug-drug interaction" defined
12-15-35-8. "Drug utilization review" or "DUR" defined
12-15-35-9. "Intervention" defined
12-15-35-10. "Overutilization or underutilization" defined
12-15-35-11. "Pharmacist" defined
12-15-35-12. "Physician" defined
12-15-35-13. "Prospective DUR" defined
12-15-35-14. "Retrospective DUR" defined
12-15-35-15. "Standards" defined
12-15-35-16. "SURS" defined
12-15-35-17. "Therapeutic appropriateness" defined
12-15-35-17.5. "Therapeutic classification" or "therapeutic category" defined
12-15-35-18. "Therapeutic duplication" defined
12-15-35-18.5. Application of chapter
12-15-35-18.7. Formulary requirements
12-15-35-19. Drug utilization review board; establishment
12-15-35-20. Membership of board
12-15-35-20.1. Conflicts of interest
12-15-35-20.5. Therapeutics committee established; members; limitations; terms; votes; meetings
12-15-35-21. Board; appointment; term
12-15-35-22. Qualifications of board members
12-15-35-23. Physician appointments; geographic balance
12-15-35-24. Reappointment of members
12-15-35-25. Chairman; compensation; expenses
12-15-35-26. Additional staff
12-15-35-27. Retrospective and prospective DUR program responsibility
12-15-35-28. Duties of the board; preferred drug list; report
12-15-35-28.5. Therapeutics committee duties
12-15-35-28.7. Submitting initial preferred drug list; limitations on restrictions; advance notice to providers; implementation; prior authorization limitation; rules
12-15-35-29. Quorum; majority vote on DUR criteria and standards for prescribing
12-15-35-30. Local practices; monitoring
12-15-35-31. Intervention; approval; requisites
12-15-35-32. Repealed
12-15-35-32.1. Annual report contents
12-15-35-33. Repealed
12-15-35-34. Confidential identifying information; release of cumulative nonidentifying information
12-15-35-35. Prior approval program for outpatient drugs; standards
12-15-35-36. Advisory committees
12-15-35-37. Medicaid state plan; inclusion of retrospective and prospective DUR program
12-15-35-38. DUR program guidelines and procedures
12-15-35-39. Retrospective DUR requisites
12-15-35-40. Prospective DUR requisites
12-15-35-41. Board activities under
12-15-35-42. Meetings
12-15-35-43. Confidentiality; pharmacist data and information
12-15-35-43.5. Prohibiting the release of proprietary or confidential information obtained under certain circumstances
12-15-35-44. Confidentiality; violations; penalty
12-15-35-45. Outpatient drug formulary; requirements
12-15-35-46. Review of proposed formulary
12-15-35-47. Review of changes to formulary
12-15-35-48. Board review of managed care organization prescription drug program
12-15-35-49. Information provided by office
12-15-35-50. Maximum allowable cost schedule for drugs; pharmacy participation in Medicaid program
12-15-35-51. Advisory committee; duties; report